Legend Biotech Corporation - American Depositary Shares (LEGN)

Earlier-line adoption and new launches fueled a sharp swing to adjusted profit.

Legend Biotech (NASDAQ:LEGN) reported 36% growth in third-quarter global net trade sales of its multiple myeloma treatment CARVYKTI, while executives said slower-than-anticipated gains in earlier-line U.S. patients and international launch delays could temper sales expectations. CARVYKTI sales reac

One of J&J's investments stands head-and-shoulders above the rest.

CARVYKTI sales surged 50% globally as company swung to profitability.

Legend Biotech (NASDAQ:LEGN) reported second-quarter 2026 results marked by continued global growth for CARVYKTI and the company’s first quarter of company-wide profitability on both an IFRS and adjusted basis, management said during its earnings call. Interim Chief Executive Officer Alan Bash said

It has been a banner year for biotech buyouts, and these are two of the prime targets.

Legend Biotech (NASDAQ:LEGN) used an investor and analyst event to highlight long-term data and physician perspectives supporting broader use of CARVYKTI, its BCMA-directed CAR T-cell therapy for multiple myeloma developed, manufactured and co-promoted with Johnson & Johnson. Chief Executive Of

Legend Biotech develops cell therapies for cancer, with a pipeline spanning hematologic malignancies and solid tumors.

Full Truck Alliance is a top digital freight platform in China, connecting shippers and truckers through tech-enabled logistics services.

Legend Biotech (LEGN) Q1 2026 Earnings Transcript

Legend Biotech (NASDAQ:LEGN) reported sharply higher first-quarter 2026 sales for CARVYKTI, its CAR T therapy for multiple myeloma, as management said demand continued to move into earlier lines of treatment and international markets expanded. Chief Executive Officer Ying Huang said the company beg

Yum China operates thousands of quick-service and casual dining restaurants across China under well-known international brands.

Futu Holdings delivers digital brokerage and wealth management services to retail and institutional clients across Asia and global markets.

Two analysts weighed in positively about the company's future.

Legend Biotech (LEGN) Q4 2025 Earnings Transcript

Legend Biotech (LEGN) Q2 2025 Earnings Transcript

Legend Biotech (LEGN) Q4 2024 Earnings Transcript

Legend Biotech (LEGN) Q1 2025 Earnings Transcript

Futu Holdings delivers digital brokerage and wealth management solutions to retail and institutional clients across Asia and global markets.

Baidu is transitioning from a search-driven advertising company into an AI infrastructure and enterprise cloud provider in China. HHLR’s exit comes as investors weigh whether this transformation will lead to sustainable growth.